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In the past few years, research has focused on the
search for new biologic factors of prognostic value.
The oncogene neu was identified by transfection of
NIH3T3 cells with DNA from rat neuroblastomas and
glioblastomas induced by perinatal treatment with the
alkylating agent nitrous-ethyl-urea. These tumors are
associated with expression of a 185-kd protein on the
surface of the tumoral cells.1
To date, the p185neu protein has been determined by
use of immunohistochemistry or Western blot analysis.
These methods give semiquantitative results and are
associated with a certain degree of subjectivity.
Quantification of the p185neu protein by means of
enzyme-linked immunosorbent assay (ELISA) has
recently been accepted. Theoretically, this procedure
for quantification of p185neu offers validated character-
istics2 that make it a good candidate for use in clinical
practice.
A lthough important in non–small cell lung cancer(NSCLC), clinical variables, pathologic staging,
and morphologic features appear to have reached the
peak of their contribution in the prediction of prognosis
of this condition.
Background: We sought to assess the relationship between tissue concentra-
tion of erb-b-2 or neu oncogene-encoded protein (p185neu) with overall sur-
vival in patients with non–small cell lung cancer.
Methods: Levels of protein p185neu were determined in 102 patients with the
diagnosis of non–small cell lung cancer. Concentration of p185neu protein
was determined by using enzyme immunoassay and evaluated by using sev-
eral variables. The relative prognostic importance of this marker and its
influence on other prognostic factors was evaluated by using the Cox regres-
sion model.
Results: The mean p185neu value in these samples was 250 ± 200 U/mg (95%
confidence interval, 210-290). This distinguished two groups within the
tumoral population: those with less than 350 U/mg and those with 350 U/mg
or greater (80th percentile). Multivariable analysis established an indepen-
dent prognostic value for protein p185neu. Patients with p185neu values of the
80th percentile or greater had a risk of death that was 2.11-fold (95% confi-
dence interval, 1.10-4.05) that of patients with values of less than 350 U/mg
(P = .03), and increases in the neu oncogene of 100 U/mg increased the prob-
ability of death by 17% (P = .02; 95% confidence interval, 1.04-1.31). 
Conclusion: This study shows that the p185neu expression is an objective and
comparable variable for the assessment of phenotypic aggressivity in
non–small cell lung cancer, and in the future, it could be included in daily
clinical practice. (J Thorac Cardiovasc Surg 2000;119:1119-25)
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PROGNOSTIC VALUE OF THE QUANTIFIED EXPRESSION OF P185c-erbB2 IN NON–SMALL CELL LUNG
CANCER
GENERAL THORACIC SURGERY
In the light of these observations, this study was
designed to assess the relationship between p185neu
protein and overall survival in NSCLC.
Patients and methods
Study population. The study population comprised 102
patients from Madrid who underwent resection for NSCLC3
in the Clinic Hospital (10 women and 92 men; mean age, 62
± 9 years; age range, 31-83 years) from October 1990 to June
1994. The surgical team was the same in all patients. Seventy
lobectomies, 3 bilobectomies, and 29 pneumonectomies were
performed; mediastinal node dissection was performed in all
patients. The distribution of the 102 patients in relation to
their histologic type in accordance with the World Health
Organization classification4 was as follows: 64 (63%)
patients were classified as having epidermoid carcinoma, 30
(30%) adenocarcinoma, and 8 (7%) undifferentiated large
cell tumors. Pathologic staging according to the TNM classi-
fication3 was as follows: 58 (57%) patients in stages IA to IB,
8 (8%) in stages IIA to IIB, and 36 (35%) in stage IIIA. On
analysis of the degree of tumoral differentiation, the tumors
were allocated to one of three groups5: 37 (32%) poorly dif-
ferentiated tumors, 55 (48%) moderately differentiated
tumors, and 23 (20%) well-differentiated tumors.
Before surgical treatment, none of the patients received
chemotherapy or radiotherapy. To assess a possible prognos-
tic value of overexpression of p185, we performed postoper-
ative follow-up studies 3 times monthly for the first 2 years
and every 6 months in the following years. Mean follow-up of
this group was 26 months (SD, 18 months; range, 1-70
months). Of all the patients in this group, 7 (7%) died in the
immediate postoperative period. During follow-up, 3 patients
died of unrelated causes, and 40 (40%) patients died of the
lung cancer.
At the time of this study, tumoral relapse had been detect-
ed in 41 (40%) of the 102 patients who underwent tumor
resection for curative purposes.
Twenty patients who had received surgical treatment for
idiopathic pneumothorax were included to establish control
levels of p185 expression as a reference value. This group
comprised 5 women and 15 men with a mean age of 48 years.
The 3 specimen types were compared through a cumulated
distribution of p185neu protein (Fig 1).
During the operations, two kinds of samples were taken,
one from the area macroscopically affected by the tumor and
the other from the region not affected by the tumor at a min-
imum distance of at least 10 cm from the tumor. When the
histopathologic study was performed, each sample was divid-
ed into two parts. One was sent to the surgical pathology
department, and the other was sent for p185neu protein mea-
surement and other determinations. Samples were washed in
cold saline solution, immediately frozen in liquid nitrogen,
and stored in a freezer at –80°C until processed.
For p185neu protein determinations, samples were
processed as followed. First they were weighed and ground,
and then the samples were homogenized and centrifuged to
obtain a supernatant. This supernatant was ultracentrifuged to
obtain the cytosol, which was distributed into aliquots for
p185neu protein determination. All the assays were blinded to
the clinical results.
p185neu protein assay. Determination of the p185 protein
was performed by use of ELISA with reagents supplied by
Oncogene Science (Uniondale, NY). ELISA consists of a
sandwich technique requiring two antibodies: one mouse
monoclonal antibody to capture the antigen and a polyclonal
rabbit antibody for its detection. The latter recognizes the
external domain of the p185 protein.6
The total cytosol protein concentration was assayed by the
method of Lowry, Rosenbrought, and Farr.7 Samples were
diluted before p185 determination to ensure a total protein
concentration of 2 to 4 mg/mL; p185 results were expressed
as units per milligram of protein.
Statistical analysis. This was a prospective cohort study,
with survival as the dependent variable. The protocol of inde-
pendent variables studied individually was tumoral stage, his-
tologic type, degree of differentiation, atypical index, ploidy,
age, and oncoprotein p185 determinations.
Survival was estimated according to the method of Kaplan
and Meier8 for independent variables to study the outcome
death. The cut-off value was established from the distribution
percentiles; the 50th percentile or between the 50th and 80th
percentile values was used to categorize patients. The sur-
vival curves of each subgroup were compared by the Breslow
exact test.
Finally, the Cox proportional risk regression model was fit-
ted to data to estimate the independent prognostic importance
of p185 protein. The included variables were those variables
analyzed in univariable study (P < .15). All interactions were
tested according to a hierarchic model. Adjusted hazard ratios
are presented with their corresponding confidence intervals
(CIs) at 95%. The model’s basic assumptions were evaluated
(proportional hazards). In each hypothesis contrast a type I
(α) error less than .05 of the null hypothesis was rejected.
Results
Description of the p185 concentration. The mean
value of oncoprotein p185neu in samples of tumoral tis-
sue of neoplastic patients was 253.9 U/mg protein
(range, 8-1050 U/mg), with an SD of 198.5 (Table I).
Analysis of the group of control patients gave a mean
concentration of p185 of 103.7 U/mg (SD, 98.0; Table I).
Mean values of the p185 protein in these 3 groups
showed a clear difference between the control group
and the group with a tumor (healthy tissue, P = .01, and
tumoral tissue, P = .004; Fig 1).
The p185 concentration and the distribution of the
results according to the patients’ characteristics are given
in Table II. Statistically significant differences were not
found in the p185 distribution in relation to histologic
type, tumoral stage, the degree of tumoral differentiation,
atypia index, or patient age. However, aneuploid samples
were most prevalent and had significantly higher p185
levels than euploid samples (P = .01).
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Analysis of survival: Influence of p185 as a prog-
nostic factor. The accumulated probability of survival
of the patients with cancer in this series was 76% at 12
months and 52% at 36 months. Follow-up median was
calculated at 32 months.
To study survival in relation to p185 values, the
p185neu 50th percentile (210 U/mg) and 80th percentile
(350 U/mg) values were used. Because significant dif-
ferences were not found between the less than 210
U/mg range and the 210 U/mg to 349 U/mg range, the
80th percentile was taken as the sole reference value
(Fig 2).
Analysis of the survival of patients in relation to the
protein p185neu value (<350 U/mg or ≥350 U/mg)
showed patients with p185neu of 350 U/mg or greater to
have a worse prognosis (P = .03), with a median sur-
vival of 16 months. At 24 months, 60% of patients with
p185neu values of less than 350 U/mg survived.
Significant differences in stratified analysis were
found between levels of p185 overexpression in the
epidermoid-type cancers, with survival being sig-
nificantly different in groups of patients with
p185neu values of 350 U/mg or greater and less than
350 U/mg (P = .03; Fig 3). 
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Table I. Descriptive study of p185neu protein analysis
in the study populations
p185 protein Median 
Variables n (U/mg)* (25th–75th percentile)
Control tissue 20 103.7 ± 98.0 90 (9–166)
Healthy tissue 68 203.2 ± 203.1 149 (100–346)
Tumoral tissue 102 253.9 ± 198.5 210 (110–312)
*Mean ± SD.
Fig 1. Cumulative distribution of the p185neu samples: control tissue (n = 20), healthy tissue (n = 68), and tumoral
tissue (n = 102).
Table II. Study of p185neu protein in relation to the
different variables studied determined in tumoral
samples collected during surgery in 102 patients with
NSCLC
p185 protein Median 
Variables n (U/mg)* (25th-75th percentile)
Histologic type
Epidermoid 64 234.7 ± 161.6 196 (110–297)
Adenocarcinoma 30 268.8 ± 211.9 251 (112–329)
Large cells 8 351.3 ± 363.8 213 (71–655)
Tumoral stage
I 58 269.6 ± 216.5 248 (105–312)
II 8 226.9 ± 145.1 183 (121–352)
IIIA 36 234.6 ± 179.5 198 (115–136)
Tumoral grade
Poor 33 253.8 ± 225.1 198 (109–266)
Moderate 46 250.2 ± 180.5 222 (111–349)
Well 20 273.4 ± 211.8 254 (124–320)
Atypia index
X 3 419.0 ± 404.0 304 (85–868)
XX 39 251.1 ± 193.4 254 (136–303)
XXX 18 270.5 ± 241.0 197 (88–371)
Ploidy
Euploidy 30 185.5 ± 87.7 178 (116–252)
Aneuploidy 53 313.9 ± 243.3 261 (128–395)
Age
<65 y 58 277.3 ± 205.9 244 (128–343)
≥65 y 42 227.0 ± 189.3 160 (100–294)
*Mean ± SD.
Protein p185neu values had no statistically significant
influence on survival in the other histologic types (ade-
nocarcinomas or undifferentiated large cells).
When tumoral stages were studied individually, global
survival significantly declined in stage I patients with
values of p185neu of 350 U/mg or greater (P = .0003; Fig
4). The median survival of stage I patients with values of
p185neu of 350 U/mg or greater was 25 months (95% CI,
1-49 months). At this time, 84% of stage I patients with
a p185neu value of less than 350 U/mg were alive.
There was no significant association between sur-
vival and protein p185 determinations in the other
tumoral stages (II and IIIA).
In the study, according to the degree of tumoral dif-
ferentiation, survival significantly declined in patients
with poorly differentiated tumors with a p185 expres-
sion above the 80th percentile (P = .05).
When studying the effect of p185 expression on sur-
vival in patients with euploid and aneuploid tumors
(flow cytometric DNA analysis9), survival was signifi-
cantly lower in euploid tumors with values of p185neu
of 350 U/mg or greater (P = .04). No significant differ-
ences were found in survival in relation to p185 expres-
sion in patients with aneuploid tumors (P = .22).
In the study on the behavior of the population
according to the degree of atypia, there was no signif-
icant association between survival and p185 values.
However, p185 levels were significantly different 
(P = .01) in patients over 65 years old. This group had
a median survival of 9 months (95% CI, 4-14 months).
In patients younger than 65 years, p185 values had no
statistically significant influence on survival (P = .22).
The p185neu variable was studied as (1) categorized
and (2) quantified (Table III):
1. Patients with a p185neu value greater than or equal
to the 80th percentile had a mortality risk 2.11-fold
(95% CI, 1.10-4.05) that of patients with values of less
than 350 U/mg (P = .03).
2. Increases in p185neu values by 100 U/mg produced
a 17% rise (95% CI, 1.04-1.31) in the mortality risk
(P = .02).




(mo) survival ± SE n
p185 protein <210 U/mg 12 67 ± 6 36
24 59 ± 7 30
36 49 ± 7 15
p185 protein 210-349 U/mg 12 87 ± 6 26
24 61 ± 9 16
36 57 ± 9 14
p185 protein ≥350 U/mg 12 56 ± 10 15
24 43 ± 10 10
36 24 ± 9 5
Fig 2. Survival of the tumoral population (NSCLC, n = 102)
according to percentiles of p185 expression (Clinic Hospital,
Madrid, Spain, 1990-1994).
Time Cumulated 
(mo) survival ± SE n
p185 protein <350 U/mg 12 84 ± 5 40
24 66 ± 7 29
36 58 ± 8 18
p185 protein ≥359 U/mg 12 58 ± 4 7
24 58 ± 14 6
36 23 ± 14 2
Fig 3. Survival in relation to the level of p185 expression in
epidermoid tumors (n = 64; Clinic Hospital, Madrid, Spain,
1990-1994).
Finally, multivariable analysis (Tables IV and V) was
applied with the variables that had yielded P values of
less than .15 in the univariate study, and the interac-
tions from stratified analysis were introduced but had
no statistical significance (P < .10).
This gave the following results: A p185neu value of
350 U/mg or greater was an independent factor of the
other variables studied. The risk of mortality was 2.53
times (95% CI, 1.25-5.13) greater in patients with these
values compared with those with a p185neu value of less
than 350 U/mg. Compared with patients with stage I
and II tumors, the mortality risk was 2.51 times (95%
CI, 1.35-4.60) greater in patients with stage IIIA
tumors, regardless of the presence of additional factors.
Discussion
Most studies in the literature on overexpression and
amplification of oncoprotein p185 used immunohisto-
chemistry as the analytic technique.10
In a previous study the authors carried out a validation
study of the ELISA technique, in which p185 determi-
nation was done by using ELISA and simultaneously by
using immunohistochemistry. The two techniques were
found to be well correlated (r = 0.85, P < .01).11
Recent studies have also demonstrated a clear corre-
lation between p185 determination by means of
enzyme immunoassay and immunohistochemistry.12,13
Both techniques can be used complementarily to mea-
The Journal of Thoracic and
Cardiovascular Surgery
Volume 119, Number 6
Cantero et al 1123
Time Cumulated 
(mo) survival ± SE n
p185 protein <350 U/mg 12 96 ± 3 45
24 86 ± 5 33
36 76 ± 7 21
p185 protein ≥350 U/mg 12 64 ± 15 7
24 54 ± 15 6
36 22 ± 13 2
Fig 4. Survival of stage I patients (n = 58) in relation to pro-
tein p185 levels (Clinic Hospital, Madrid, Spain, 1990-1994).
Table III. Univariate hazard ratios by a Cox regression
model (survival study) in 102 patients with NSCLC
Variables HR 95% CI P value
Histologic type
Large cells vs adenocarcinoma 3.09 1.12–8.52 .03
Epidermoid carcinoma vs 1.29 0.62–2.67 .5
adenocarcinoma
Tumor stage
II vs I 1.82 0.61–5.40 .3
IIIA vs I 3.01 1.59–5.73 .001
Tumor grade
Moderate vs well 1.27 0.50–3.20 .6
Poor vs well 1.97 0.78–4.96 .2
Atypia index
XX vs X 0.49 0.14–1.69 .3
XXX vs X 0.57 0.15–2.10 .4
Age
≥65 vs <65 1.44 0.78–2.64 .2
Ploidy
Aneuploidy vs euploidy 2.59 1.19–5.64 .01
p185 protein categorized variable
≥350 vs <350 U/mg 2.11 1.10–4.05 .03
p185 protein quantified variable
100 U/mg 1.17 1.04–1.31 .02
HR, Hazard ratio.
Table IV. Hazard ratios adjusted by the Cox regression
model (categorized variable, survival study) in 102
patients diagnosed with NSCLC
Variables Adjusted HR 95% CI P value
P185 protein categorized 
variable
≥350 vs <350 U/mg 2.53 1.25–5.13 .01
Tumor stage
IIIA vs I + II 2.51 1.35–4.60 .004
Age
≥65 vs <65 y 1.74 0.91–3.35 .10
HR, Hazard ratio.
Table V. Hazard ratio adjusted by a Cox regression
model (quantified variable, survival study)
Variables Adjusted HR 95% CI P value
P185 protein quantified 
variable
100 U/mg 1.24 1.16–1.31 .003
Tumor stage
IIIA vs I + II 2.88 1.55–5.36 .001
Age
≥65 vs <65 y 1.74 0.92–3.29 .09
HR, Hazard ratio.
sure p185 values in tissue. Determination by ELISA
rectifies the subjectivity of the immunohistochemical
technique and provides a more precise distinction
between levels 0 and 1.
Several studies have demonstrated that overexpres-
sion of p185 measured by immunohistochemistry is an
independent prognostic factor in survival and recur-
rence in NSCLC.14,15 In this study, by using the quanti-
tative technique ELISA, which other authors had previ-
ously used in studies on recurrence,11 we reached the
same conclusions when studying survival.
Results of p185 expression measured by immunohis-
tochemistry in relation to histologic type vary from one
study to the next.14-16
Data obtained in the different studies that measure p185
expression by immunohistochemistry are similar to those
that use ELISA and demonstrate that there is no signifi-
cant association between p185 expression and increasing
age or more advanced stages, although higher levels of
p185 are observed in well-differentiated tumors.14-16
Marks and colleagues17 indicated that fixation
decreases the sensitivity of p185 detection by immuno-
histochemistry compared with the use of frozen sam-
ples. In fact, p185 expression determined by immuno-
histochemistry can underestimate the true incidence
and level of expression in these tumors.
Díez and colleagues11 showed that TNM staging and
histologic type are the most important predictive vari-
ables in patients with p185 values below 100 U/mg,
with increasing risk attributed to this marker on
increasing p185 levels. Therefore in patients with p185
values above 600 U/mg, the negative influence of this
protein becomes even more important than the influ-
ence of stage or histologic type.
This fact emphasizes the inadvisability of a dichoto-
mous interpretation of the results (positive vs negative),
at least when this variable is used as a prognostic mark-
er of the disease. Other more sensitive techniques for
detection and estimation of the level of p185 expression
(ELISA) give additional information, especially in epi-
dermoid tumors.11 Therefore the relation found
between levels of p185 expression and survival is dif-
ferent when the ELISA technique is used from when
data are obtained by immunohistochemical techniques.
A recent study15 reported overexpression of p185 in
all histologic types of NSCLC and showed this to be a
marker of poor prognosis in these tumors. These
authors showed an additive effect of the expression of
oncogenes p53 and p185, which act independently in
tumorgenesis.
Expression of c-erb-B-2 has been shown to be asso-
ciated with a worse outcome in cancers of the
breast,17,18 stomach,1 ovary,19 and lung.15 These obser-
vations were made from p185 determinations by means
of immunohistochemistry, except in the studies on
breast12 and lung cancers,11 which used the ELISA
technique and also showed an association with poor
outcome.
In NSCLC some series record a lower survival in
stage I patients in which p185 expression was deter-
mined by means of immunohistochemistry.15
An association between the level of p185 expres-
sion and poor outcome was not found in any of the
global series of NSCLC, which used immunohisto-
chemistry for p185 determinations. However, an
association was found in some series that focused on
tumors of a specific stage15 or histologic type.16 This
should be studied in relation to all the other factors
that can be associated with or can affect survival.
That is, a series of patients with lung cancer is com-
posed of different subgroups of stages and histologic
types. Possibly, as suggested previously by other
authors,20 p185 expression is not only associated
with poor outcome in early stages but also with a par-
ticular histologic type. Therefore whether global sur-
vival is found to be affected by this variable would
depend on the composition of the group.
Data that refer to the influence of p185 on survival
suggest that this has the greatest prognostic signifi-
cance in stage I tumors. In later stages a poor outcome
is not dependent on p185 expression and must be relat-
ed to other factors.
In our study an association was found between histo-
logic type and p185 expression. In contrast with other
authors who had used immunohistochemical tech-
niques and reported that p185 expression was a marker
of poor outcome in adenocarcinomas, our results
revealed a lower survival associated with higher levels
of p185 expression in patients with epidermoid tumors.
These findings suggest that overexpression of p185 in
epidermoid tumors is in itself of vital importance in
tumoral development, whereas in the other histologic
types, because there is no significant increase in p185
expression, the combination of other genetic alterations
or alteration of the erb-b-2 gene possibly secondary to
other genetic aberrations21 would have to occur.
The higher values in healthy tissue from the tumoral
group could occur as a result of some other process; for
example, smoking induced early genetic alterations
that may occur in a premalignant state. The wide range
of p185 values in tumoral specimens could be
explained because of the different histologic type.
One of the objectives of this study was to identify
patients with a poor prognosis in the early stages to use
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more aggressive treatment than that currently used and
therefore increase survival. Unfortunately, in vitro
studies on a range of human neoplasms, including lung
cancer, have shown that tumors that express p185 are
more resistant to chemotherapy and radiotherapy.22
This must be verified in patients with NSCLC. If these
patients are proven to present a greater resistance to
adjuvant therapies, it will be necessary to seek new
alternative therapies or approaches, such as neoadju-
vant chemotherapy, in stage I patients with p185 levels
in the cytosol of 350 U/mg or greater. One of the lines
of research that has already begun in this field deals
with obtaining tumoral cell cultures. Knowledge of the
in vitro sensitivity to certain drugs of cell lines derived
from tumors with a probable poor evolution, deter-
mined by the presence of biologic markers of poor
prognosis, could be the beginnings of a more personal-
ized and effective therapy.
This study shows that p185 expression is an objective
variable for the assessment of phenotypic aggressivity in
NSCLC. In the future, a classification derived from a
multiple regression study that combines the TNM classi-
fication for the anatomic description of the extent of
tumoral spread and one or more variables to determine
the aggressivity of the tumor could result in the genera-
tion of a specific prognostic index for each patient.
Determination of p185 expression could be a good can-
didate for use in this multifactorial predictive model.
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